Grifols (GRFS) Other financing activities (2011 - 2020)
Grifols' (GRFS) quarterly Other financing activities came in at $5.3 million in Q1 2020, down 54.36% YoY from $11.6 million in Q2 2019, and down 52.75% on a QoQ basis from $11.2 million in Q4 2019.
Grifols (GRFS) Other financing activities (2011 - 2020) Analysis & Trends
Grifols (GRFS) has 10 years of Other financing activities data on file, last reported at $5.3 million in Q1 2020.
- Quarterly Other financing activities fell 54.36% year-over-year to $5.3 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $27.4 million (up 185.1% YoY) and the FY2025 annual result came in at $43.1 million, down 22.49% from the prior year.
- Other financing activities slipped to $5.3 million in Q1 2020, from $11.2 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $182.0 million in Q4 2017 to a low of -$103.6 million in Q1 2017.
- A 5-year average of $15.7 million and a median of $5.3 million in 2020 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2016 — Other financing activities slumped 1745.48% — and 2017, when it soared 2902.98%.
- Tracing GRFS's Other financing activities over 5 years: stood at $6.1 million in 2016, then surged by 2902.98% to $182.0 million in 2017, then sank by 100.39% to -$700817.4 in 2018, then surged by 1701.54% to $11.2 million in 2019, then plunged by 52.75% to $5.3 million in 2020.
- The last three Other financing activities figures came in at $5.3 million (Q1 2020), $11.2 million (Q4 2019), and $11.6 million (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 5.30 Mn |
| Mar 31, 2020 | 5.30 Mn |
| Dec 31, 2019 | 11.22 Mn |
| Dec 31, 2019 | 11.22 Mn |
| Mar 31, 2019 | 11.62 Mn |
| Mar 31, 2019 | 11.62 Mn |
| Dec 31, 2018 | -700,817.41 |
| Dec 31, 2018 | -700,817.41 |
| Jun 30, 2018 | -2.48 Mn |
| Jun 30, 2018 | -2.48 Mn |
| Mar 31, 2018 | 1.18 Mn |
| Mar 31, 2018 | 1.18 Mn |
| Dec 31, 2017 | 181.96 Mn |
| Dec 31, 2017 | 181.96 Mn |
| Jun 30, 2017 | 116.86 Mn |
| Jun 30, 2017 | 116.86 Mn |
| Mar 31, 2017 | -103.56 Mn |
| Mar 31, 2017 | -103.56 Mn |
| Dec 31, 2016 | 6.06 Mn |
| Dec 31, 2016 | 6.06 Mn |